SQZ Biotechnologies Company Overview
Pro stress-test →SQZ Biotechnologies is a clinical-stage biotechnology company focused on unlocking the full potential of cell therapies to benefit patients with cancer, autoimmune and infectious diseases. The company's proprietary Cell Squeeze® technology offers the unique ability to deliver multiple biological materials into many patient cell types to engineer a broad range of potential therapeutics.
Strategic Profile
Pro stress-test →With accelerated production timelines under 24 hours and the opportunity to eliminate preconditioning and lengthy hospital stays, the company's approach could change the way people think about cell therapies. The lead product candidate is SQZ-PBMC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors.
Competitive Landscape
Pro stress-test →Key competitors include Regenxbio, Meditope Biosciences, Alvotech, CytomX Therapeutics, and CaroGen, which operate across cell therapy, biologics, and gene therapy segments. SQZ differentiates through its Cell Squeeze® platform technology and accelerated production timelines, though it faces competition from both established cell therapy developers and emerging platforms.
Industry Context
SQZ Biotechnologies Company operates in Cell therapy manufacturing and development.
Key facts
Founded: 2013 · Headquarters: Watertown, US · Employees: 53 · Revenue: N/A · Market cap: $0.7M